Literature DB >> 26460786

Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy.

Janki Bhakta1, Jacquelyn Bainbridge1, Laura Borgelt2.   

Abstract

BACKGROUND: Many antiepileptic drugs (AEDs) have the potential to cause teratogenicity. We evaluated eight antiepileptic drugs (AEDs) classified as Federal Drug Administration (FDA) pregnancy category D, X, or N designations and having documented teratogenic effects. These include carbamazepine, ethosuximide, fosphenytoin, phenobarbital, phenytoin, primidone, topiramate, and valproate. Women with epilepsy (WWE) may need one or more of these AEDs for seizure control but may be unaware of the potential teratogenicity associated with their use. In utero exposure to AEDs increases the risks for both congenital malformations and other teratogenic defects. Given that approximately 50% of pregnancies are unintended, it is likely that women with epilepsy taking these medications could unknowingly put a growing fetus at risk. For women using contraception while taking these medications, many choose combined hormonal contraceptives (CHCs). Drug-drug interactions exist between AEDs and CHCs that may decrease contraceptive efficacy. The aim of this study was to evaluate prescribing patterns for potentially teratogenic AEDs and contraceptive use in WWE of childbearing ability, including those with potential drug-drug interactions. This study also determined the number of WWE of childbearing ability prescribed potentially teratogenic AEDs and documentation of a pregnancy or contraception plan.
METHODS: This was a retrospective, observational study of WWE age 15-44 years, of childbearing ability, prescribed an AED from July 1, 2011 to June 30, 2012, and who had an appointment at the University of Colorado Hospital Outpatient Neurology Clinic (Anschutz Medical Campus).
RESULTS: One hundred fifteen women with an average age of 30.7 years and various types of seizures were evaluated. The majority of patients were prescribed topiramate (34/115, 30%) or carbamazepine (27/115, 23%). Of the women, 30/115 (26%) had a documented contraception method when taking a potentially teratogenic AED. Of these women prescribed contraception, most (18/30, 60%) used an oral combined hormonal contraceptive or progestin-only pill, a majority of which had a potential for a drug-drug interaction with their AEDs (16/18, 89%). Less than 7% of women received counseling on a contraception plan, and 18% of subjects received counseling on a pregnancy plan.
CONCLUSIONS: Most WWE of childbearing ability taking potentially teratogenic AEDs were not using contraception. Those using contraception frequently had a method that has a significant drug-drug interaction which reduces the effectiveness of contraception. Women with epilepsy of childbearing ability prescribed an AED should be using effective contraception or participating in active discussions about pregnancy planning to avoid unplanned pregnancies and possible teratogenic effects of these AEDs. Documentation about pregnancy planning or contraceptive use in WWE of childbearing ability is minimal and should be discussed at least annually. It is critical for providers to discuss with WWE of childbearing ability the benefits and risks of various AED treatments; the need to select appropriate, effective contraception when pregnancy is not desired; and the importance of counseling regarding contraceptive or pregnancy planning.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiepileptic drug; Contraception; Epilepsy; Teratogen

Mesh:

Substances:

Year:  2015        PMID: 26460786     DOI: 10.1016/j.yebeh.2015.08.004

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  8 in total

1.  Antiseizure drugs and women: Challenges with contraception and pregnancy.

Authors:  Tejal Patel; Kelly A Grindrod
Journal:  Can Pharm J (Ott)       Date:  2020-09-27

2.  Antiseizure drugs for women with epilepsy: Before, during, and after pregnancy.

Authors:  Tejal Patel; Kelly Grindrod
Journal:  Can Fam Physician       Date:  2020-04       Impact factor: 3.275

3.  Effects of lacosamide "a novel antiepileptic drug" in the early stages of chicken embryo development.

Authors:  Mesut Mete; Beyhan Gurcu; Fatih Collu; Ulkun Unlu Unsal; Yusuf Kurtulus Duransoy; Mehmet Ibrahim Tuglu; Mehmet Selcuki
Journal:  Childs Nerv Syst       Date:  2016-07-29       Impact factor: 1.475

Review 4.  Neurological Complications of Pregnancy.

Authors:  H Steven Block
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

5.  Knowledge regarding teratogens among women of childbearing age at a large tertiary care center in Saudi Arabia.

Authors:  Wejdan Alhamdan; Afaf Moukaddem; Nourh AlOtaibi; Adibah Aledrees; Nada Alhatem; Nada Alshehri; Samaher Alfaraj; Maysoon Aladham
Journal:  J Family Med Prim Care       Date:  2020-06-30

Review 6.  Contraception for women with epilepsy: counseling, choices, and concerns.

Authors:  Arne Reimers
Journal:  Open Access J Contracept       Date:  2016-04-19

7.  Lacosamide intake during pregnancy increases the incidence of foetal malformations and symptoms associated with schizophrenia in the offspring of mice.

Authors:  Beatriz López-Escobar; Rut Fernández-Torres; Viviana Vargas-López; Mercedes Villar-Navarro; Tatyana Rybkina; Eloy Rivas-Infante; Ayleen Hernández-Viñas; Concepción Álvarez Del Vayo; José Caro-Vega; José A Sánchez-Alcázar; Antonio González-Meneses; M Ángel Carrión; Patricia Ybot-González
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

8.  Cranial neural tube defect after trimethoprim exposure.

Authors:  Nor Linda Abdullah; Renuka Gunasekaran; Siti Waheeda Mohd-Zin; Bee-Hui Lim; Pramila Maniam; Anis Shuhada Mohd-Salleh; Meow-Keong Thong; Zamri Chik; Noreena Nordin; Zaliha Omar; Julia Patrick Engkasan; Dharmendra Ganesan; Zakaria Nurul Aiezzah; Azlina Ahmad-Annuar; Noraishah Mydin Abdul-Aziz
Journal:  BMC Res Notes       Date:  2018-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.